ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announce that Dr. Wu Zhuli ("Dr. Wu") was appointed as a Chief Medical Officer of the Group with effect from June 9, 2025, responsible for the establishment and management of the Company's clinical team, clinical trial research, clinical development and registration. Dr. Wu is based in China and reports directly to Dr. Tian Wenzhi, the founder, Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of the Company. Dr. Wu has over 13 years of extensive experience in the clinical development of new drugs in hematology, oncology and immunology.
Prior to joining the Group, Dr. Wu worked at renowned pharmaceutical companies, including Janssen Pharmaceuticals, Roche, and Shanghai Fosun Pharmaceutical (Group) Co. Ltd.* ("Fosun Pharma"). From 2018 to 2025, Dr. Wu served as the senior vice president and chief medical officer (oncology) for China at Fosun Pharma's R&D center, where she led clinical development strategies for 16 innovative molecules.
Under her leadership, over 40 investigational new drug (IND) applications were approved, five new drug applications (NDA) were submitted, with three successfully approved, and three breakthrough therapy designations were awarded. Luvometinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, whose development she led, achieved market launch at a groundbreaking pace, becoming China's first local innovative drug for the treatment of histiocytic proliferative diseases/histiocytic tumors and pediatric neurofibromatosis type 1-associated plexiform neurofibroma, addressing a critical gap in clinical treatment. Beyond her corporate leadership, Dr. Wu serves as a member of the Third Chinese Society of Clinical Oncology (CSCO) Clinical Trials Professional Committee and a member of the Anti-cancer Drug Clinical Research Professional Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) Dr. Wu received clinical medicine education at Peking University and clinical oncology at Peking University Cancer Hospital, in China from September 2001 to July 2009.
